Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
Hemab Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$29.68M | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.49M | – |
See a number that looks wrong?